In recent years, the pharmaceutical supply chain has undergone significant transformations driven by technological advancements and regulatory changes. Additionally, the COVID-19 pandemic highlighted the importance of supply chain resilience. As a result, there's a growing emphasis on diversification of suppliers, strategic stockpiling, and risk assessment to mitigate disruptions caused by unforeseen events. Furthermore, personalized medicine and biopharmaceuticals have gained traction, leading to shorter production cycles and smaller batch sizes, which in turn necessitate agile supply chain models.